Drugs from a novel class designed to lower cholesterol levels and reduce the risk of heart attacks, strokes and cardiovascular death are posting dismal results and may never make it to the market. The drug class, known as CETP inhibitors block a protein that transfers HDL cholesterol to LDL cholesterol, which results in higher HDL – or good cholesterol – and lower LDL – or bad cholesterol – levels. Researchers have been trying for years to develop a successful CETP inhibitor in an effort to take a bite out of the market share of statin drugs, the gold standard for lowering ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.